12-02-05

AF

PTO/SB/21 (02-04).

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE r the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 09/393,590 Application Number September 9, 1999 Filing Date **TRANSMITTAL FORM** Elizabeth Moyer First Named Inventor (to be used for all correspondence after initial filing) 1645 Art Unit **Examiner Name** S. J. N. Devi Total Number of Pages in This Submission 31242-701.201 Attorney Docket Number ENCLOSURES (Check all that apply) After Allowance communication to Fee Transmittal Form Drawing(s) Technology Center (TC) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information **Provisional Application** Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please identify below): return Extension of Time Request Terminal Disclaimer receipt postcard Express Abandonment Request Request for Refund Information Disclosure Statement CD, Number of CD(s) and PTO/SB/08A with 4 references Certified Copy of Priority Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Albert P. Halluin, Reg. No. 25,227, WILSON SONSINI GOODRICH & ROSATI Individual name Signature Date November 30, 2005 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below Typed or printed name FILED VIA EXPRESS MAIL (EV 711412528 US) ON NOVEMBER 30, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Signature

NOV 3 0 2005 YN THE UNITED STATES PA	TENT AND TRADEMARK OFFICE
Inventor: Efizabeth Moyer, et al.	Group Art Unit: 1645
Serial Number: 09/393,590	Examiner: S. J. N. Devi
Filing Date: September 9, 1999	CONFIRMATION NO: 2967
Title: STABLE LIQUID FORMULATIONS OF BOTULINUM TOXIN	

FILED BY EXPRESS MAIL ON: November 30, 2995

EXPRESS MAIL LABEL NO.: EV 711412528 US

Commissioner of Patents
P.O. Box 1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Alexandria, VA 22313-1450

Applicant(s) hereby submit(s) an Information Disclosure Statement along with attached form(s) PTO/SB/08A. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§1.97-1.98, as indicated below.

Applicant(s) respectfully request(s) that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicant(s) further request that the Examiner initial and return the attached form(s) PTO/SB/08 in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

becaus	CFR §1.97	b). This Information Disclosure Statement should be considered by the Office
	(1)	It is being filed within 3 months of the application filing date of a national application and is other than a continued prosecution application under §1.53(d);  OR
	(2)	It is being filed within 3 months of entry of a national stage as set forth in §1.491 in an international application;

	<del></del> 1	(2)	OR
		(3)	It is being filed before the mailing date of the first Office Action on the merits; OR
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.
	specifi office closes	ed in 37 action u prosecut	(c). Although this Information Disclosure Statement is being filed after the period CFR §1.97(b), above, it is filed before the mailing date of the earlier of (1) a final nder §1.113, (2) a notice of allowance under §1.311, or (3) an action that otherwise ion on the merits, this Information Disclosure Statement should be considered because ed by one of:
		a certif	ication as specified in §1.97(e) provided concurrently herewith; OR
			of \$180.00 as set forth in \$1.17(p) authorized below, enclosed, or included with the nt of other papers filed together with this statement.
	date of	f the earl	(d). Although this Information Disclosure Statement is being filed after the mailing tier of (1) a final office action under §1.113 or (2) a notice of allowance under §1.311, I before payment of the issue fee and should be considered because it is accompanied
	A.	a certif	fication as specified in §1.97(e); and
	В.		of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included with the nt of other papers filed together with this Statement.
			(e). A certification signed by an Attorney of Record is provided herewith as required §§1.97(b) and (c).
$\boxtimes$	37 CF.	R §1.98(	(a)(2). The content of the Information Disclosure Statement is as follows:
	$\boxtimes$	Copies herewi	of each of the references listed on the attached Form PTO/SB/08A are enclosed th.  OR
		-	of U.S. Patent Documents (issued patents and patent publications) listed on the d Form PTO/SB/08A are NOT enclosed.  AND/OR
		-	of Foreign Patent Documents and/or Non Patent Literature Documents listed on the d Form PTO/SB/08A are enclosed in accordance with 37 CFR §1.98(a)(2).
		<b>.</b>	AND/OR
	Ц		of pending unpublished U.S. patent applications are enclosed in accordance with R \$1.98(a)(2)(iii).

$\boxtimes$	37 CF	R $\S1.98(a)(3)$ . The Information Disclosure Statement includes non-English patents and/orces.
		Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent publication or other information provided that is not in English is provided herewith.
		The German references cited herein are dictionary entries of the word, "saline."
·		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation of the non-English language reference(s) is provided herewith
		ed are copies of search report(s) from corresponding patent application(s), submitted in the copies of search report(s) from corresponding patent application(s), submitted in the copies of the attached certification under 37 CFR §1.97(e)(1).
	\$180.00	thorization. The Commissioner is hereby authorized to charge the above-referenced fees of and charge any additional fees or credit any overpayment associated with this nication to Deposit Account No. 23-2415 (Docket No. 31242-701.201).
		Respectfully submitted,
		WILSON SONSINI GOODRICH & ROSATI
	•	Δ Δ Δ
Dated:	Novem	ber 30, 2005  By: Albert P. Halluin, Registration No. 25,227
Palo A (650) 4	ge Mill I Ito, CA 9 93-9300 ner No. (	Road 04304-1050

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO
INFORMATION DISC

Sheet

NOV 3 0 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

(Use as many sheets as necessary)

Complete if Known			
Application Number 09/393,590			
Filing Date	September 9, 1999		
First Named Inventor	Elizabeth Moyer		
Art Unit	1645		
Examiner Name	S. J. N. Devi		
Attorney Docket Number	31242-701.201		

	U.S. PATENT DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or . Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Collin, P. H., et al. Saline. In Pons Fachworterbuch Medizin dictionary (p. 368).	
		Unseld, D. W. (1991). Saline. In Medical Dictionary of the English and German Languages (p. 280).	
		Urban & Schwarzenberg. Saline. In Roche Lexikon Medizin dictionary (p. 1400).	
		Walber de Gruyter. Saline. In Psychyrembel Klinisches Worterbuch dictionary (p. 1483).	
		Decision Revoking the European Patent No. 1112082 dated November 22, 2005 from the European Patent Office	
		·	
		· · ·	

Examiner	Date	
Signature	Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.